NEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced tha

U.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the C

NEW HAVEN, Conn., July 06, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced tha

NEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced tha

ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge”

Data from LIBERTY can provide important insight into the VYD2311 clinical profile by direct comparis

NEW HAVEN, Conn., June 16, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced enr

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Invivyd (NASDAQ:IVVD) with a Buy a

Invivyd Inc (NASDAQ:IVVD) has dosed the first participants in its LIBERTY Phase 3 trial, a study tes

Invivyd Inc (NASDAQ:IVVD) has dosed the first participants in its LIBERTY Phase 3 trial, a study tes

LIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA

NEW HAVEN, Conn., June 09, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced tha

NEW HAVEN, Conn., June 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced tha

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and e

NEW HAVEN, Conn., June 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the

NEW HAVEN, Conn. , May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced tha

Dow Jones falls 400 points, while Gemini Space Station Inc (NASDAQ: GEMI) sees 25.7% jump after stro

Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript

Invivyd NASDAQ: IVVD said its first quarter of 2026 was marked by continued progress in its pivotal

Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Es

Invivyd (NASDAQ:IVVD) reported quarterly losses of $(0.13) per share which missed the analyst consen

Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growt

Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody a

Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody a

NEW HAVEN, Conn., May 07, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical

NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that

Elia to speak at the premier gathering of policy makers, industry leaders, and health experts betwee

U.S. stocks fell, Dow Jones down 100+ points. BlackBerry (NYSE:BB) reported strong Q4 results and sa

Invivyd expands VYD2311 COVID study, delays timeline to Q3 2026, and advances measles antibody VMS06

Confirmed, pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION study of VYD2311 accum

U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-

Invivyd (NASDAQ:IVVD) reported quarterly earnings of $0.02 per share which beat the analyst consensu

LIBERTY is part of the Company's broader REVOLUTION clinical program designed to elaborate the p

Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical eff

Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% gr

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and e

BTIG analyst Thomas Shrader initiates coverage on Invivyd (NASDAQ:IVVD) with a Buy rating and ann